Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245260 | 0.89 | HDAC1 (0.61) | KDM4EHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL13949968 | 0.84 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL23055100 | 0.81 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1HDAC1HDAC3 | |
| SCHEMBL1374685 | 0.80 | HDAC1 (0.74) | SMN1; SMN2ALDH1A1HDAC1HDAC3HDAC2 | |
| SCHEMBL1374684 | 0.80 | HDAC1 (0.74) | SMN1; SMN2ALDH1A1HDAC1HDAC3HDAC2 | |
| SCHEMBL13949927 | 0.80 | DRD2 (0.67) | HDAC1HDAC3HDAC2HDAC8MAPT | |
| SCHEMBL8744966 | 0.79 | KDM4E (0.71) | KDM4ESMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL724056 | 0.78 | HDAC1 (0.69) | SMN1; SMN2HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL1486886 | 0.78 | HDAC1 (0.69) | SMN1; SMN2HDAC1HDAC3HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL8745027 | 0.78 | KDM4E (0.70) | KDM4ESMN1; SMN2ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1870399-A1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007021682-A1 | METHOD OF USE OF DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KDM4E 330/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KDM4E 330/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | KDM4E 317/4885SMN1; SMN2 3167/4885ALDH1A1 812/4885 |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | HDAC3, HDAC5, HDAC1 | KDM4E 413/4885SMN1; SMN2 3303/4885ALDH1A1 1042/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KDM4E 330/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.